| [1] |
PODWIKA S E, JENKINS T M, KHOKHAR J K, et al. Optimal age for genetic cancer predisposition testing in hereditary SMARCA4 ovarian cancer families: how young is too young?[J]. Gynecol Oncol Rep, 2020, 32: 100569.
|
| [2] |
LEE E K, ESSELEN K M, KOLIN D L, et al. Combined CDK4/6 and PD-1 inhibition in refractory SMARCA4-deficient small-cell carcinoma of the ovary, hypercalcemic type[J]. JCO Precis Oncol, 2020, 4: 736-742.
|
| [3] |
CONNOR Y D, MIAO D A, LIN D I, et al. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: clinical features of a single family and comparison of large cohorts[J]. Gynecol Oncol, 2020, 157(1): 106-114.
doi: 10.1016/j.ygyno.2019.10.031
|
| [4] |
HUGHES I A, HOUK C, AHMED S F, et al. Consensus statement on management of intersex disorders[J]. J Pediatr Urol, 2006, 2(3): 148-162.
doi: 10.1016/j.jpurol.2006.03.004
pmid: 18947601
|
| [5] |
FOULKES W D, KAMIHARA J, EVANS D G R, et al. Cancer surveillance in gorlin syndrome and rhabdoid tumor predisposition syndrome[J]. Clin Cancer Res, 2017, 23(12): e62-e67.
doi: 10.1158/1078-0432.CCR-17-0595
|
| [6] |
PEJOVIC T, MCCLUGGAGE W G, KRIEG A J, et al. The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type[J]. Gynecol Oncol Rep, 2019, 28: 47-49.
|
| [7] |
YOUNG R H, OLIVA E, SCULLY R E. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases[J]. Am J Surg Pathol, 1994, 18(11): 1102-1116.
pmid: 7943531
|
| [8] |
CALLEGARO-FILHO D, GERSHENSON D M, NICK A M, et al. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): a review of 47 cases[J]. Gynecol Oncol, 2016, 140(1): 53-57.
doi: 10.1016/j.ygyno.2015.11.004
|
| [9] |
WITKOWSKI L, GOUDIE C, RAMOS P, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type[J]. Gynecol Oncol, 2016, 141(3): 454-460.
doi: S0090-8258(16)30071-3
pmid: 26975901
|
| [10] |
JAMY O, YAGHMOUR G, HARE F, et al. Population-based analysis of the clinical features of primary small cell carcinoma of the ovary[J]. Anticancer Res, 2015, 35(5): 3091-3095.
pmid: 25964600
|
| [11] |
ESTEL R, HACKETHAL A, KALDER M, et al. Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literature[J]. Arch Gynecol Obstet, 2011, 284(5): 1277-1282.
doi: 10.1007/s00404-011-1846-5
pmid: 21298438
|
| [12] |
RAY-COQUARD I, MORICE P, LORUSSO D, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv1-iv18.
doi: 10.1093/annonc/mdy001
|
| [13] |
WANG Y M, CHEN S Y, KARNEZIS A N, et al. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type[J]. J Pathol, 2017, 242(3): 371-383.
doi: 10.1002/path.4912
|
| [14] |
WANG Y M, CHEN S Y, COLBORNE S, et al. Histone deacetylase inhibitors synergize with catalytic inhibitors of EZH2 to exhibit antitumor activity in small cell carcinoma of the ovary, hypercalcemic type[J]. Mol Cancer Ther, 2018, 17(12): 2767-2779.
doi: 10.1158/1535-7163.MCT-18-0348
pmid: 30232145
|
| [15] |
SOLDI R, GHOSH HALDER T, WESTON A, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer[J]. PLoS One, 2020, 15(7): e0235705.
doi: 10.1371/journal.pone.0235705
|
| [16] |
LANG J D, HENDRICKS W P D, ORLANDO K A, et al. Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multikinase inhibition[J]. Clin Cancer Res, 2018, 24(8): 1932-1943.
doi: 10.1158/1078-0432.CCR-17-1928
pmid: 29440177
|
| [17] |
XUE Y B, MEEHAN B, MACDONALD E, et al. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary[J]. Nat Commun, 2019, 10(1): 558.
doi: 10.1038/s41467-018-06958-9
|
| [18] |
JELINIC P, RICCA J, VAN OUDENHOVE E, et al. Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade[J]. J Natl Cancer Inst, 2018, 110(7): 787-790.
doi: 10.1093/jnci/djx277
pmid: 29365144
|
| [19] |
TISCHKOWITZ M, HUANG S D, BANERJEE S, et al. Small-cell carcinoma of the ovary, hypercalcemic type-genetics, new treatment targets, and current management guidelines[J]. Clin Cancer Res, 2020, 26(15): 3908-3917.
doi: 10.1158/1078-0432.CCR-19-3797
pmid: 32156746
|
| [20] |
ZHANG F F, WANG W J, LONG Y, et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response[J]. Cancer Commun (Lond), 2018, 38(1): 60.
|
| [21] |
BERCHUCK A, WITKOWSKI L, HASSELBLATT M, et al. Prophylactic oophorectomy for hereditary small cell carcinoma of the ovary, hypercalcemic type[J]. Gynecol Oncol Rep, 2015, 12: 20-22.
|
), KANG Mingyi1,2, WANG Hui3, XU Jing1,2, SHI Yue1, TAO Xiang4, MA Fenghua5, TAN Haowen6, KANG Yu1,2(
